Key facts
- It has raised $5.0M; the latest was Early Stage VC ($5.0M) in Mar 2026.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Tutelix
- ·The full record, as it builds
Funding rounds
No funding rounds for Tutelix are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Tutelix
Developer of a thermoresponsive oncology spacer system intended to create temporary tissue separation during prostate radiotherapy. The company designs a ready-to-use injectable hydrogel with high visibility across imaging modalities, sculptable volume adjustment, and cohesive in body gelation, enabling radiation oncology teams to improve targeting accuracy, reduce rectal dose exposure, and enhance procedural safety and simplicity.
- Sector
- Healthcare
- HQ
- Alexandria, Australia
- Founded
- 2024
- Employees
- 5
- Website
- tutelix.com/
- Ownership
- Privately Held (backing)
Tutelix doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Tutelix shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Tutelix in its N-PORT filings yet. We sweep new filings monthly.